anti igm  (Valiant)

Journal: Clinical and Vaccine Immunology : CVI

Article Title: Double-Antigen Enzyme-Linked Immunosorbent Assay for Detection of Hepatitis E Virus-Specific Antibodies in Human or Swine Sera

doi: 10.1128/CVI.00186-07

Figure Lengend Snippet: Scatter chart of OD values obtained by the new sandwich ELISA for sera known to contain anti-HEV IgM or IgG antibodies, or both, and sera from other patients or healthy controls. The solid horizontal line represents the COV. Neg, negative; Pos, positive.

Article Snippet: The negative and positive control samples for anti-HEV IgG and IgM antibodies were from the in-house preparations used for the commercial kit (MP Biomedicals).

Techniques: Sandwich ELISA

Journal: Cell Death and Differentiation

Article Title: EBV BCL-2 homologue BHRF1 drives chemoresistance and lymphomagenesis by inhibiting multiple cellular pro-apoptotic proteins

doi: 10.1038/s41418-019-0435-1

Figure Lengend Snippet: A subset of human BLs harbour EBV in a form of viral latency that involves expression of BHRF1 and these BLs are protected from diverse apoptotic stimuli. a Western blotting for EBV latent proteins EBNA1, EBNA2, LMP1, BHRF1, lytic protein BZLF1 and the cellular protein ACTIN (loading control) in a panel of representative BL derived cell lines that have different associations with EBV. Included are EBV-negative BLs (BL41 and BL2), Latency I BLs (Eze-BL and Sav-BL) that express EBNA1 protein only, and Wp-restricted BLs (Oku-BL and Sal-BL) that express EBNA1 and BHRF1 (and EBNA3A, 3B, 3C and truncated EBNA-LP, data not shown). As a control for western blotting, an LCL (X50-7) was included that expresses a Latency III pattern of infection, involving expression of EBNA1, EBNA2, low BHRF1 and LMP1 (plus additionally EBNAs 3A, 3B, 3C and -LP and LMP2s, data not shown). Lytic cycle-induced Akata-BL (lytic Akata-BL) cells were included as a control for cells undergoing viral replication and expressing high levels of the immediate early lytic antigen, BZLF1, and the early antigen BHRF1. b BL cell lines, Oku-BL and Sal-BL cells, that carry EBV in a Wp-restricted latency, involving expression of BHRF1, were significantly more protected from death induced by ionomycin (1 µg/mL) and anti-IgM Fab2 antibody fragments (5 µg/mL), both analysed after 48 h of treatment, compared with the Latency I BL cells, Eze-BL and Sav-BL. Cell death was determined by flow cytometry after staining with Annexin V and propidium iodide (PI) and cell death induction was calculated by comparing to control, untreated cells. Data are shown as the mean and standard deviation of three independent experiments. Unpaired two-tailed t -tests were performed to assess the significance of the differences between cells carrying EBV in Wp-restricted latency and Latency I patterns of infection (**** p ≤ 0.0001)

Article Snippet: Etoposide (Sigma), ionomycin (Sigma), anti-IgM Fab2 antibody fragments (MP Biomedicals), Roscovitine and Staurosporine (both Cell Signalling Technologies) were added at the concentrations indicated in the figures.

Techniques: Expressing, Western Blot, Derivative Assay, Infection, Flow Cytometry, Staining, Standard Deviation, Two Tailed Test

Journal: Blood

Article Title: The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo

doi: 10.1182/blood-2011-10-386417

Figure Lengend Snippet: Abrogation of signaling downstream of the BCRs and of CXCR4 and CXCR5 receptors. Displayed are immunoblots from CLL cells from 1 representative patient of 9 patients, that were either unstimulated or stimulated for 10 minutes with anti-IgM (αIgM,

Article Snippet: To determine the efficacy of the inhibitor to antagonize BCR-derived prosurvival signals after BCR triggering with anti-IgM, CLL samples (107 cells/mL) were preincubated in complete RPMI medium with or without PCI-32765 for 30 minutes at 37°C, and then stimulated by the addition of 10 μg/mL anti-IgM (polyclonal goat F(ab′)2 fragments to human IgM; MP Biomedicals).

Techniques: Western Blot

Journal: Blood

Article Title: The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo

doi: 10.1182/blood-2011-10-386417

Figure Lengend Snippet: PCI-32765 inhibits anti-IgM and NLC-mediated prosurvival signals in CLL cells. (A) Contour plots of a representative CLL sample, depicting CLL cell viabilities after 24, 48, and 72 hours of incubation with anti-IgM in the presence or absence of PCI-32765,

Article Snippet: To determine the efficacy of the inhibitor to antagonize BCR-derived prosurvival signals after BCR triggering with anti-IgM, CLL samples (107 cells/mL) were preincubated in complete RPMI medium with or without PCI-32765 for 30 minutes at 37°C, and then stimulated by the addition of 10 μg/mL anti-IgM (polyclonal goat F(ab′)2 fragments to human IgM; MP Biomedicals).

Techniques: Incubation

Journal: Viruses

Article Title: Monitoring of Anti-Hepatitis E Virus Antibody Seroconversion in Asymptomatically Infected Blood Donors: Systematic Comparison of Nine Commercial Anti-HEV IgM and IgG Assays

doi: 10.3390/v8080232

Figure Lengend Snippet: Comparison of different anti-hepatitis E virus (HEV) assays regarding the course of immune response during seroconversion of 10 blood donors with acute HEV infection. The course of immune response of 10 blood donors with autochthonous HEV infection is displayed, determined by 10 different commercially available anti-HEV immunoassays. The day of the detection of HEV RNA by PCR screening was defined as day 0 [ 28 ], confirmation of the presence of HEV RNA is indicated by gray shading. The period of positive testing results is displayed by light grey bars for the five HEV immunoglogulin (Ig)M-specific assays, by white bars for the four HEV IgG-specific assays and by dark grey bars for the HEV all antibody assay (see Table 1 for the encoding of the kits). Bars are starting at half of the interval between the last negative and first positive sample and last until half of the interval between last positive and first negative sample. The Assure HEV IgM Rapid Test (MP-Bior-IgM) was only performed with limited samples for donor 3 (day 0–126), donor 5 (day 0–40), donor 8 (day 28–52) and donor 9 (day 0–57). SC/O: signal-to-cutoff; AB: antibody.

Article Snippet: Moreover, the signal levels of assays determining the presence of anti-HEV IgM differ; for example, in samples of donor 2, the Wantai, MP-Bio-rapid and Euroimmun assays provide clear positive results, whereas the Mikrogen and MP-Bio assaysassay determine borderline results.

Techniques: Infection, Polymerase Chain Reaction